SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-149802
Filing Date
2024-05-30
Accepted
2024-05-30 07:18:01
Documents
15
Period of Report
2024-05-28
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d836893d8k.htm   iXBRL 8-K 26484
2 EX-99.1 d836893dex991.htm EX-99.1 7213
6 GRAPHIC g836893dsp5.jpg GRAPHIC 8151
  Complete submission text file 0001193125-24-149802.txt   175250

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA glue-20240528.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE glue-20240528_lab.xml EX-101.LAB 18738
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE glue-20240528_pre.xml EX-101.PRE 11708
18 EXTRACTED XBRL INSTANCE DOCUMENT d836893d8k_htm.xml XML 3773
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40522 | Film No.: 241000706
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)